US 9161935
Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy
granted A61KA61K31/4704A61K45/06
Quick answer
US patent 9161935 (Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.
- Grant date
- Tue Oct 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61K, A61K31/4704, A61K45/06, A61P, A61P1/00